로딩 중…
StockDiggingStockDigging

NeopharmCO.,LTD.

092730· KOSDAQ
₩16,970-3.19%
2026-06-19

Price Chart

NeopharmCO.,LTD.+14.97%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap271.99B KRW
Revenue136.80B KRW
Net Income8.25B KRW
Total Assets225.35B KRW
Net Assets192.11B KRW
Employees171
Value
P/E32.98x
P/B1.42x
PEG1.58x
P/S1.99x
EV/EBITDA29.63x
FCF Yield10.01%
Profitability
ROE4.29%
ROA3.66%
Op. Margin5.95%
Revenue Growth14.60%
Earnings Growth20.84%
Financial Health
Debt Ratio117.31%
Total Debt1.06B KRW
FCF27.23B KRW
Cash31.92B KRW
Current Ratio5.75x
Net Debt/EBITDA-3.79x
Dividend
Div. Yield4.28%
Div. Growth25.00%
Performance
1Y Return14.97%
1M Return-6.24%
From 52W High-25.08%
1Y MDD-25.87%
Trading
Volume35,828 shares
Foreign Own.26.11%
Per Share
EPS1,829 KRW
BPS12,282 KRW

Company Info

CEO 김양수
Employees 171
Founded 2000
HQ 대전 유성구, KR

Established in 2000, the company is a KOSDAQ-listed cosmetics manufacturer. Its largest shareholder became It's Hanbul after the 2017 merger of Hanbul Cosmetics and It's Skin. The company owns cosmetic brands such as Atopalm, Real Barrier, Derma:B, Tl's, and Zeroid, with 83% domestic sales and 17% exports. Utilizing its proprietary MLE formulation technology, it develops products by understanding skin barrier function and expands its business through new formulation development. Neopharm is headquartered in Yuseong-gu, Daejeon.